FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade
April 21, 2017 -- FDA today approved Renflexis (infliximab-abda) for multiple indications. Renflexis is administered by intravenous infusion. This is the second FDA-approved biosimilar to U.S.-licensed Remicade.
A biosimilar product is a biological... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 21, 2017 Category: Drugs & Pharmacology Source Type: news
FDA Clears Second Remicade Biosimilar (Renflexis) FDA Clears Second Remicade Biosimilar (Renflexis)
The FDA approves infliximab-abda (Renflexis, Samsung Bioepis) for multiple indications.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 21, 2017 Category: Dermatology Tags: Rheumatology News Alert Source Type: news
Dental implants in a young patient on Remicade infusions for cervical spondylitis?
I have a 39 year old male patient for dental implants who presents with cervical spondylosis and gets an infusion of infliximab (Remicaide) every 6 weeks. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - April 5, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Cases Surgical Source Type: news
What Causes Uveitis?
Discussion
Inflammation of the middle layer of the eye, or uvea, is termed uveitis. Uveitis can be divided into anterior, intermediate or posterior uveitis by involving the anterior (iris and ciliary body), intermediate (vitreous) or posterior (choroid and usually retina) compartments. Panuveitis involves all 3 compartments. Duration can also be used to classify uveitis. Acute is 6 weeks and > 3 months is chronic persistent uveitis. Episodic periods of inactivity and reactivity that last more than 3 months are called recurrent uveitis. A third way to characterize uveitis is if it is granulomatous or not. Uveitis increas...
Source: PediatricEducation.org - April 3, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Remicade for Rheumatoid Arthritis Treatment
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 27, 2017 Category: Journals (General) Source Type: news
AS: TNF Inhibitors Differ in Uveitis Risk (CME/CE)
(MedPage Today) -- Adalimumab and infliximab have lowest risk (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 18, 2017 Category: Geriatrics Source Type: news
Infliximab Biosimilar Safe and Effective for Inflammatory Bowel Disease Infliximab Biosimilar Safe and Effective for Inflammatory Bowel Disease
The infliximab biosimilar CT-P13 (Remsima) is safe and effective against inflammatory bowel disease (IBD), according to a systematic review and meta-analysis.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 14, 2017 Category: Surgery Tags: Gastroenterology News Source Type: news
Infliximab Use Not Tied to Malignancy in Pediatric IBD Infliximab Use Not Tied to Malignancy in Pediatric IBD
Immunosuppressive therapy with infliximab (Remicade, Janssen) for inflammatory bowel disease (IBD) in pediatric patients is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis (HLH), according to a Janssen study.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 7, 2017 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
Biosimilar of costly inflammatory bowel disease therapy found safe and effective
(Wiley) Treatment of Crohn's disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab (which targets tumour necrosis factor alpha), but at considerable cost. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 3, 2017 Category: Global & Universal Source Type: news
Infliximab vs. Adalimumab in Crohn's Disease Infliximab vs. Adalimumab in Crohn's Disease
Do the anti-TNF agents infliximab and adalimumab have comparable response characteristics? Are concomitant immunomodulators necessary for optimal response?Alimentary Pharmacology & Therapeutics (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 28, 2017 Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news
Remicade vs. Humira
Title: Remicade vs. HumiraCategory: MedicationsCreated: 2/27/2017 12:00:00 AMLast Editorial Review: 2/27/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 27, 2017 Category: Drugs & Pharmacology Source Type: news
Johnson & Johnson Announces Further Patent and Trademark Office Action Related to REMICADE ®
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 23, 2017 Category: Pharmaceuticals Source Type: news
ICU Medical closes $900m buyout of Pfizer ’ s Hospira infusion pump biz
ICU Medical (NSDQ:ICUI) this week closed its $900 million acquisition of the Hospira infusion pump business from Pfizer (NYSE:PFE), confirming last year’s rumors that the drug giant was looking to sell the business.
The deal, which was scaled back from $1 billion last month, called for ICU Medical to offer 3.2 million new shares, or $419.3 million, and $275 million in cash, along with an additional possible $225 million in cash based on performance milestones through the end of 2019. The transaction will put Hospira’s infusion systems business, including IV pumps, solutions, disposables and “certain other...
Source: Mass Device - February 8, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Hospital Care Mergers & Acquisitions Wall Street Beat Hospira Inc. ICU Medical Inc. Pfizer Source Type: news
Getting back into the swing of things: Jake ’s journey with Crohn’s disease
It was a cloudy, September day at the Country Club of Miami in South Florida. Jake Goodstat, a high school sophomore and varsity golf player, approached the ninth green. He walked up to his ball with putter in hand, took a deep breath and gently tapped the ball to make the putt.
He says this was the hole where he cinched second place in the 2016 South Florida Junior Golf Tournament.
“It was the greatest feeling in the world to know that I placed,” recalls Jake, a Florida teen who underwent surgery two months prior to treat his Crohn’s disease. “Before my surgery, I would register for a tournament, end up in ...
Source: Thrive, Children's Hospital Boston - January 26, 2017 Category: Pediatrics Authors: Maureen McCarthy Tags: Diseases & Conditions Our Patients’ Stories Athos Bousvaros Center for Inflammatory Bowel Disease (IBD) Crohn's disease Robert Shamberger Source Type: news
Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab
Long-term outcomes of patients with steroid-refractory acute severe ulcerative colitis (UC) are similar whether treated with cyclosporine or infliximab, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
